Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
An update from Quantum Biopharma ( (TSE:QNTM) ) is now available.
Quantum BioPharma has engaged MZ Group to enhance its investor relations and shareholder communications, aiming to increase visibility in the capital markets. This strategic move highlights Quantum BioPharma’s focus on developing solutions for brain disorders and alcohol misuse, with products like unbuzzd™ and rekvry™ addressing excessive alcohol consumption. The collaboration with MZ Group is expected to bolster Quantum Biopharma’s market presence and attract investment, given the substantial unmet needs in its targeted health areas.
More about Quantum Biopharma
Quantum BioPharma is a biopharmaceutical company focused on developing innovative assets and biotech solutions for neurodegenerative, metabolic, and alcohol misuse disorders. The company, through its subsidiary Lucid Psycheceuticals, is advancing its lead compound Lucid-MS, which targets myelin degradation in multiple sclerosis. Additionally, Quantum BioPharma has developed the unbuzzd™ product and retains a significant stake in Celly Nutrition, which handles its over-the-counter version.
YTD Price Performance: 200.25%
Average Trading Volume: 2,382,468
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $22.43M
See more data about QNTM stock on TipRanks’ Stock Analysis page.
